New Light-Based scan could spot prostate cancer faster

NCT ID NCT02394223

Completed Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new imaging technique called Full Field Optical Coherence Tomography (FFOCT) to see if it can detect prostate cancer in biopsy samples as well as standard microscope analysis. Researchers compared FFOCT results to the usual pathology exam in 91 men with elevated PSA levels. The goal was to see if FFOCT could provide a quicker or more detailed diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Full Field Optical Coherence Tomography (FFOCT) imaging procedure
What this could lead to: If successful, FFOCT could provide a faster, more accurate way to diagnose prostate cancer from biopsy samples.
What could go wrong: This is a small, completed study with 91 participants, and the technique is still experimental. It may not prove better than standard methods in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH PSA LEVEL 4.0 NG/ML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH PSA LEVEL 4.0 NG/ML

Contacts and locations

Locations

Assistance Publique - Hôpitaux de Paris Cochin Hospital

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.